Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
View Patent ↗This invention also provides a method to prevent, control, and treat a lipid metabolism disorder, a billary disorder, cardiovascular disease, obesity or an endocrine disorder by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cGMP-dependent phosphodiesterases.
1. A method for treating dyslipidemia comprising administering to a patient in need thereof an effective dosage of a guanylate cyclase receptor agonist having the sequence of SEQ ID NO:9, wherein said agonist is a [4:12,7:15] bicyclic peptide.
2. A method of claim 1 , further comprising administering an effective dose of inhibitor of a cGMP-specific phosphodiesterase.
3. The method of claim 2 , wherein said inhibitor of cGMP-specific phosphodiesterase is administered either concurrently or sequentially with said guanylate cyclase receptor agonist.
4. The method of claim 2 , further comprising administering an effective dose of a fibrate, a lipid altering agent, or a HMG-CoA reductase inhibitor.
5. The method of claim 4 , wherein said fibrate, lipid altering agent, or HMG-CoA reductase inhibitor is administered either concurrently or sequentially with said guanylate cyclase receptor agonist.
6. The method of claim 1 , further comprising administering an effective dose of an anti-diabetic agent.
7. The method of claim 6 , wherein said anti-diabetic agent is administered either concurrently or sequentially with said guanylate cyclase receptor agonist.
8. The method of claim 1 , further comprising administering an effective dose of an anti-obesity agent.
9. The method of claim 8 , wherein said anti-obesity agent is administered either concurrently or sequentially with said guanylate cyclase receptor agonist.
10. The method of claim 2 , further comprising administering a fibrate, a lipid altering agent, a HMG-CoA reductase inhibitor, an anti-diabetic agent or an anti-obesity agent.
11. The method of claim 10 , wherein said fibrate, lipid altering agent, HMG-CoA reductase inhibitor, anti-diabetic agent or anti-obesity agent is administered either concurrently or sequentially with said inhibitor of a cGMP-specific phosphodiesterase.